SuperworthZai Lab EPS ZLAB
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.18
- Latest quarter, Q2 FY26
- −$0.05
- Fiscal year 2025
- −$0.16
Zai Lab's earnings per share was −$0.18 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.05.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.16 | n/a |
| FY2024 | −$0.25 | n/a |
| FY2023 | −$0.35 | n/a |
| FY2022 | −$0.46 | n/a |
| FY2021 | −$2.76 | n/a |
| FY2020 | −$3.46 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.05 | n/a | −$0.18 | |
| Q1 FY26 | −$0.05 | n/a | −$0.17 | |
| Q4 FY25 | −$0.05 | n/a | −$0.16 | |
| Q3 FY25 | −$0.03 | n/a | −$0.19 | |
| Q2 FY25 | −$0.04 | n/a | −$0.20 | |
| Q1 FY25 | −$0.04 | n/a | −$0.24 | |
| Q4 FY24 | −$0.08 | n/a | −$0.25 | |
| Q3 FY24 | −$0.04 | n/a | −$0.27 | |
| Q2 FY24 | −$0.08 | n/a | −$0.30 | |
| Q1 FY24 | −$0.05 | n/a | −$0.35 | |
| Q4 FY23 | −$0.10 | n/a | −$0.35 | |
| Q3 FY23 | −$0.07 | n/a | −$0.31 |
Against its peers
Companies in Drug Manufacturers - General nearest Zai Lab's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ZLABZai Lab | −$0.18 | |
| NRIXNurix Therapeutics | $2.31 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| Peer median | $2.61 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Zai Lab
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.